<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654691</url>
  </required_header>
  <id_info>
    <org_study_id>CIPN-2015</org_study_id>
    <nct_id>NCT02654691</nct_id>
  </id_info>
  <brief_title>Chronic Neuropathy Following Chemotherapy</brief_title>
  <acronym>DOLORISK-CIPN</acronym>
  <official_title>DOLORISK: Understanding Risk Factors and Determinants for Neuropathic Pain - Chronic Neuropathy Following Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Pain Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mentis Cura</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neuroscience Technologies S.L.P</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Pain Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study which is a follow-up of a previous prospective questionnaire study.
      All patients who previously participated in the study will receive a new questionnaire and
      will be invited for a clinical examination.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chemotherapy-induced peripheral neuropathy</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>For case definition of neuropathy, Tesfaye et al. 2010 will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotherapy-induced neuropathic pain</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>Neuropathic pain grading system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory abnormalities after chemotherapy assessed with quantitative sensory testing (QST).</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>Modified German Research Network on Neuropathic Pain QST protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuronal excitability changes after chemotherapy assessed with threshold tracking.</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression using the Patient Reported Outcomes Measurement Information System (PROMIS).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression using the Hospital Anxiety and Depression Scale (HADS).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue using the Patient Reported Outcomes Measurement Information System (PROMIS).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using EuroQol (EQ-5D).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personality using the 10-item Personality Inventory (TIPI).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personality using the International Personality Item Pool (IPIP).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain catastrophizing using the Pain Catastrophizing Scale(PCS).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphology of small fibers in cornea after chemotherapy by Corneal Confocal Microscopy (CCM).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Samples DNA</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>Potential gene associations in the development of painful neuropathy. It is not currently defined what will measured and reported, but the genetic analysis will be focused on genetic variants that determined pain sensibility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity and interference by Patient Reported Outcomes Measurement Information System (PROMIS).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain descriptors by Douleur Neuropathique 4 (DN4).</measure>
    <time_frame>5-Year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain descriptors by Neuropathic Pain Symptom Inventory (NPSI).</measure>
    <time_frame>5-Year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy using the Toronto Clinical Scoring System (TCSS).</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>Total Neuropathy Score, National Cancer Institute-Common Toxicity Criteria (NCI-CTC),the Michigan Neuropathy Screening Instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy using the Total Neuropathy Score.</measure>
    <time_frame>5-year follow-up</time_frame>
    <description>Total Neuropathy Score,the Michigan Neuropathy Screening Instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy using the Michigan Neuropathy Screening Instrument (MNSI).</measure>
    <time_frame>5-year follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Peripheral Nervous System Diseases</condition>
  <condition>Chronic Pain</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent chemotherapy for a high-risk mamma-cancer and a high-risk
        colon-cancer from the period of 2011-2012 and who participated in a prospective
        questionnaire study (Ventzel et al. 2015).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients who have participated in a prospective questionnaire study

        Exclusion Criteria:

          -  Not able to visit in person.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristine J Bennedsgaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital and Aarhus University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Pain Research Center, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain. 2016 Mar;157(3):560-8. doi: 10.1097/j.pain.0000000000000404.</citation>
    <PMID>26529271</PMID>
  </reference>
  <reference>
    <citation>Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303. Review. Erratum in: Diabetes Care. 2010 Dec;33(12):2725.</citation>
    <PMID>20876709</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data is shared among collaborators (DOLORisk consortium)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

